Novo Nordisk moves HC to stop Sun Pharma’s weight-loss drug launch(Soban News)

The dispute centres on Novo Nordisk’s Indian patents for semaglutide, which it markets globally as Ozempic and Wegovy for Type 2 diabetes and weight management

​The dispute centres on Novo Nordisk’s Indian patents for semaglutide, which it markets globally as Ozempic and Wegovy for Type 2 diabetes and weight management by Soban News (international And National News)